NCT04460911View on ClinicalTrials.gov

Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.

CompletedOBSERVATIONAL
Enrollment

317

Participants

Timeline

Start Date

October 19, 2019

Primary Completion Date

April 1, 2022

Study Completion Date

April 1, 2022

Conditions
Breast Cancer
Trial Locations (1)

10017

Pfizer United States, New York

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04460911 - Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting. | Biotech Hunter | Biotech Hunter